Lonza Group AG (LONN) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.085x

Based on the latest financial reports, Lonza Group AG (LONN) has a cash flow conversion efficiency ratio of 0.085x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF783.00 Million ≈ $989.92 Million USD) by net assets (CHF9.19 Billion ≈ $11.61 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Lonza Group AG fund operations to measure how many days the company can operate on defensive assets alone.

Lonza Group AG - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Lonza Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lonza Group AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lonza Group AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Advanced Info Service Public Company Limited
BK:ADVANC
0.311x
Las Vegas Sands Corp
NYSE:LVS
0.623x
KERING.UNSP.ADR 1/10 EO 4
F:PPXB
N/A
Kinross Gold Corp
TO:K
0.124x
Guotai Junan Securities Co Ltd
SHG:601211
0.066x
Gold Fields Limited
F:EDG
0.048x
Carnival Corporation
NYSE:CCL
0.097x
Halliburton Company
NYSE:HAL
0.025x

Annual Cash Flow Conversion Efficiency for Lonza Group AG (2004–2025)

The table below shows the annual cash flow conversion efficiency of Lonza Group AG from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Lonza Group AG market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CHF9.19 Billion
≈ $11.61 Billion
CHF1.17 Billion
≈ $1.48 Billion
0.127x -6.23%
2024-12-31 CHF9.39 Billion
≈ $11.87 Billion
CHF1.27 Billion
≈ $1.61 Billion
0.136x -6.80%
2023-12-31 CHF9.51 Billion
≈ $12.03 Billion
CHF1.39 Billion
≈ $1.75 Billion
0.146x +52.24%
2022-12-31 CHF10.66 Billion
≈ $13.48 Billion
CHF1.02 Billion
≈ $1.29 Billion
0.096x -22.80%
2021-12-31 CHF9.82 Billion
≈ $12.42 Billion
CHF1.22 Billion
≈ $1.54 Billion
0.124x -24.52%
2020-12-31 CHF6.88 Billion
≈ $8.70 Billion
CHF1.13 Billion
≈ $1.43 Billion
0.164x +9.29%
2019-12-31 CHF6.57 Billion
≈ $8.30 Billion
CHF986.00 Million
≈ $1.25 Billion
0.150x -12.69%
2018-12-31 CHF6.29 Billion
≈ $7.95 Billion
CHF1.08 Billion
≈ $1.37 Billion
0.172x +26.43%
2017-12-31 CHF6.18 Billion
≈ $7.81 Billion
CHF841.00 Million
≈ $1.06 Billion
0.136x -57.39%
2016-12-31 CHF2.35 Billion
≈ $2.98 Billion
CHF752.00 Million
≈ $950.73 Million
0.319x -8.00%
2015-12-31 CHF2.13 Billion
≈ $2.70 Billion
CHF741.00 Million
≈ $936.82 Million
0.347x +53.06%
2014-12-31 CHF2.13 Billion
≈ $2.69 Billion
CHF483.00 Million
≈ $610.64 Million
0.227x -7.65%
2013-12-31 CHF2.13 Billion
≈ $2.69 Billion
CHF522.00 Million
≈ $659.95 Million
0.246x -16.80%
2012-12-31 CHF2.41 Billion
≈ $3.04 Billion
CHF710.00 Million
≈ $897.63 Million
0.295x +214.59%
2011-12-31 CHF2.36 Billion
≈ $2.98 Billion
CHF221.00 Million
≈ $279.40 Million
0.094x -55.40%
2010-12-31 CHF2.39 Billion
≈ $3.02 Billion
CHF502.00 Million
≈ $634.66 Million
0.210x +19.06%
2009-12-31 CHF2.39 Billion
≈ $3.02 Billion
CHF422.00 Million
≈ $533.52 Million
0.177x +80.58%
2008-12-31 CHF1.79 Billion
≈ $2.26 Billion
CHF175.00 Million
≈ $221.25 Million
0.098x -72.54%
2007-12-31 CHF1.81 Billion
≈ $2.29 Billion
CHF644.00 Million
≈ $814.19 Million
0.356x +34.68%
2006-12-31 CHF1.61 Billion
≈ $2.03 Billion
CHF425.00 Million
≈ $537.31 Million
0.264x -4.59%
2005-12-31 CHF1.49 Billion
≈ $1.88 Billion
CHF413.00 Million
≈ $522.14 Million
0.277x +100.10%
2004-12-31 CHF1.28 Billion
≈ $1.62 Billion
CHF178.00 Million
≈ $225.04 Million
0.139x --

About Lonza Group AG

SW:LONN Switzerland Diagnostics & Research
Market Cap
$43.17 Billion
CHF34.15 Billion CHF
Market Cap Rank
#811 Global
#14 in Switzerland
Share Price
CHF488.90
Change (1 day)
-1.51%
52-Week Range
CHF467.40 - CHF586.60
All Time High
CHF769.70
About

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more